<DOC>
	<DOC>NCT00612079</DOC>
	<brief_summary>This study aims to further validate and extend our previous findings insofar that the effect of the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole on sensorimotor gating processes and its relationship to cognitive performance shall be explored.</brief_summary>
	<brief_title>The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Sertindole</mesh_term>
	<criteria>Age: 1840 Gender: male Axis I Disorders: lifetime DSM IV diagnosis according to DIAX of alcohol or illicit drug dependence. No lifetime DSM IV diagnosis according to DIAX of a major affective, psychotic, anxiety disorder, eatingdisorder as defined above. Axis II Disorders: lifetime DSM IV diagnosis of personality disorder according to SCIDII. Family history: lifetime history of 1st degree relative (parents and siblings) of a major affective, psychotic, or anxiety disorder as defined above. ECG: QTcinterval &gt;450 msec. Systolic blood pressure &lt;100 mmHg Bradycardia (Hf &lt; 50/Min) und Arrhythmias Hypokalemia or Hypomagnesemia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Sertindole</keyword>
	<keyword>sensory gating</keyword>
	<keyword>PPI</keyword>
	<keyword>P50 suppression</keyword>
	<keyword>CANTAB</keyword>
	<keyword>Effect of Sertindole on sensory gating (P50 suppression)</keyword>
	<keyword>on sensorimotor gating (PPI)</keyword>
	<keyword>and cognition (CANTAB)</keyword>
</DOC>